<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81844">
  <stage>Registered</stage>
  <submitdate>8/02/2007</submitdate>
  <approvaldate>23/02/2007</approvaldate>
  <actrnumber>ACTRN12607000140459</actrnumber>
  <trial_identification>
    <studytitle>Phase 2, 'Proof of Principle', Placebo Controlled, Randomised, Parallel Group Pilot Study of the Effect of a New Combined Acne Treatment in Patients with Mild to Moderate Acne.</studytitle>
    <scientifictitle>Pilot study in patients with mild to moderate acne utilising a facial cleanser, topical gel and oral supplement compared to placebo for treatment of acne.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Mild to Moderate Acne vulgaris</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Three products will be used twice daily in the trial.                                                                                                                                                                                                                              A topical gel containing nicotinamide (4% w/w) and sandalwood oil (2% w/w) as the actives, a cosmetic facial cleanser and an oral supplement containing a combination of vitamins and minerals (Zinc 12.5mg, Nicotinamide 25mg, Vitamin B6 25mg Vitamin E 25IU, Vitamin C 125mg, Linseed oil 250mg and Vitamin A 1250IU).                                                                                                                                                                                                                    Products will be used twice daily i.e. Face will be cleansed with facial cleanser, topical gel will be applied to affected area and 1x capsule will be taken. This process is repeated twice daily i.e. morning and night. These products will be compared against matching placebos i.e. identical formulations as the treatment minus the actives.                                                                                    There will be 2 treatment groups- active and placebo.                                                                                                                                                                                                                                  Active group will take Active topical gel, Active facial cleanser and Active oral supplement. </interventions>
    <comparator>Placebo group will take Placebo topical gel, Placebo facial cleanser and Placebo oral supplement. Trial duration is 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Two grade improvement in Investigators Global Assessment (IGA) </outcome>
      <timepoint>Determined at 0, 4, 8 and 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in Inflammatory Lesion Count</outcome>
      <timepoint>Determined at 0, 4, 8 and 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with mild to moderate inflammatory acne; of any racial/ethnic group.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Oral retinoid use within 2 years of entry into the study; Systemic acne therapies within 4 weeks of entry into the study; Subjects with predominantly comedonal acne; Subjects with predominant retention acne.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>eligible patients will be randomised to the study using sequentially numbered dealed envelopes</concealment>
    <sequence>To allocate the patients into different groups a Binomial distribution random number generator was used.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Double blind, subjects and investgator/assessor are blinded.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>LifeSource Group Holdings Pty Ltd</primarysponsorname>
    <primarysponsoraddress>29-31 Solent Cct Baulkham Hills NSW 2153</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>LifeSource Group Holdings Pty Ltd.</fundingname>
      <fundingaddress>29-31 Solent Cct 
Baulkham Hills NSW 2153</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a pilot study to test in a small number of patients a holistic approach to acne treatment utilising a facial cleanser and topical gel treatment combined with an oral supplement combining natural ingredients which should not cause local irritation or lead to resistant organisms.  The unique combination of natural ingredients aims to both cleanse the skin and target internal factors that will assist to promote healthy skin and to help alleviate acne.  The Sponsor is looking to develop a suitable natural alternative to currently available pharmaceutical products for the treatment of mild to moderate acne.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Royal Melbourne Hospital
Parkville Victoria 3050</ethicaddress>
      <ethicapprovaldate>12/06/2007</ethicapprovaldate>
      <hrec>2007.032</hrec>
      <ethicsubmitdate>1/02/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor George Varigos</name>
      <address>Department of Dermatology
Royal Melbourne Hospital
Grattan St
Parkville VIC 3050</address>
      <phone>+61 3 93474233</phone>
      <fax />
      <email>george.varigos@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nadine Ismiel</name>
      <address>Suite 402
29-31 Solent Cct
Baulkham Hills NSW 2153</address>
      <phone>+61 2 88509444</phone>
      <fax>+61 2 88509445</fax>
      <email>nadine@lifesourcegroup.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>